Ivacaftor (IVA), the first CFTR modulator approved by the FDA in 2012, is a potentiator used originally for the treatment of patients with CF and at least one G551D; since then, it has been approved for more mutations. The gene discussed is CFTR; the disease is cystic fibrosis.